Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — Cantor Virtual Healthcare Conference 2020
24 slides from Eyepoint's conference presentation, Sep 15, 2020
Slide 1: Cantor Virtual Healthcare Conference September 15, 2020
CANTOR VIRTUAL HEALTHCARE CONFERENCE SEPTEMBER 15, 2020 NASDAQ: EYPT Exhibit 99.1
Slide 2: Forward Looking
FORWARD LOOKING Various statements made in this presentation are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future,
Slide 3: Company Overview
COMPANY OVERVIEW Ocular Disease Focus Portfolio of commercial- and clinical-stage assets targeting attractive areas of unmet need in ocular diseases Compelling Pipeline Includes EYP-1901 a potential six-month sustained release anti-VEGF treatment for wet age-related macular degeneration positioned f
Slide 4: Ocular Disease Focused Pipeline
1 Alimera Sciences, Inc. owns worldwide rights to ILUVIEN® for DME and rights for YUTIQ® for non-infectious posterior uveitis in the EMEA with a royalty payable to EyePoint. 2 Rights for China, Hong Kong, Taiwan, Macau , Korea and certain SE Asia countries licensed to Ocumension with a royalty on sa
Slide 5: Durasert - Proven Sustained Release Delivery
Four FDA-Approved Products with Multiple Programs in Development DURASERT® - Proven Sustained Release Delivery Sustained-release delivery of small molecule drugs to the back of the eye Release profile allows design of treatment duration from months to years Administration during Physician office vis
Slide 6: EYP-1901 - Six-Month Sustained-Release Anti-VEGF Product Candidate
EYP 1901 - Six-Month Sustained-Release Anti-VEGF Product Candidate Opportunity in Wet AMD, Diabetic Retinopathy, and Retinal Vein Occlusion
Slide 7: EYP-1901 Product Candidate Overview
EYP-1901 Product Candidate Overview Anti-VEGF intravitreal therapy with sustained, consistent delivery of drug over at least 6 months. Initial clinical target – wet AMD Utilizes Durasert technology and an anti-VEGF small molecule, vorolanib – a tyrosine kinase inhibitor (TKI) Vorolanib previously st
Slide 8: EYP-1901 Vorolanib Mechanism of Action at Receptor
EYP-1901 Vorolanib– Mechanism of Action at Receptor Vorolanib
Slide 9: EYP-1901 Vorolanib Background
Oncologist. 2019 Apr; 24(4): 455–e121. Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors EYP-1901 Vorolanib Background Vorolanib - developed on the same chemical scaffold as sunitinib Targets
Slide 10: IC50 Data Compared to Sunitinib
IC50 Data Compared to Sunitinib The inhibition constant of sunitinib for VEGFR (Ki) is reported to be low (5 ng/g), an indication on strong inhibition. Since Ki is related to IC50, similar inhibition (Ki) is expected for vorolanib EYP-1901 Vorolanib Background The most important targets of ocular ne
Slide 11: Vorolanib (X-82) Clinical Study Ph1
Phase 1 Trial – open label, 24 weeks, dose escalation, no control, oral delivery. 80 % of eyes enrolled previously treated. 4 eyes treatment naïve. Study completed by Tyrogenix, Inc. 1Jackson TL et al. JAMA Ophthalmology July 2017 Volume 135, Number 7, 2017 EYP-1901 Vorolanib (X-82) Clinical Study –
Slide 12: Phase 1 Trial - Rescue Injections
Phase 1 Trial - Rescue Injections EYP-1901 Vorolanib (X-82) Clinical Study – Ph1 25 of 35 completed at the 6 Mo Follow up
Slide 13: Phase 1 Trial - Change in CST from Baseline
Phase 1 Trial - Change in CST from Baseline through Week 24 EYP-1901 Vorolanib (X-82) Clinical History
Slide 14: Phase 2b Trial (Apex) in wAMD - Number of Anti-VEGF Injections
*Normalized for number of months on study. Study completed by Tyrogenex, Inc. Phase 2b Trial (Apex) in wAMD – Oral Administration - Number of Anti-VEGF Injections EYP-1901 Vorolanib (X-82) Clinical Study Ph2 For subjects followed ≥ 6 months, number of anti-VEGF injections per year* Placebo n=33 50
Slide 15: EYP-1901 Phase 1 Study Plan
EYP-1901 Phase 1 Study Plan Approximately 20 patients with wet AMD responsive to previous anti-VEGF therapy enrolled in US sites Primary endpoint - safety (AE rates and severity); BCVA and central subfield thickness secondary Rescue with anti-VEGF’s if necessary according to industry standard clinic
Slide 16: EYP-1901 - Next Steps and Development Plan
EYP-1901 - Next Steps and Development Plan Q3 2020 Q4 2020 1H 2021 GLP Toxicology Study Phase 1 Trial Type B Pre-IND meeting with FDA in January 2020 GLP toxicology study initiated in March 2020–unaffected by COVID-19 shut-downs IND filing in Q4 2020 with Phase 1 initiation to follow Initial data ex
Slide 17: Commercial Programs
Commercial Programs ~ > a E Ww te t -- : = a EYEPOINT PHARMACEUTICALS
Slide 18: DEXYCU and YUTIQ Commercial Programs
Postoperative inflammation following ocular surgery Chronic non-infectious uveitis affecting the posterior segment of the eye Single long-lasting treatment compared with complicated eyedrop regimen Permanent and specific J-Code with solid reimbursement experience Co-Promotion with ImprimisRX in plac
Slide 19: YUTIQ - Three-Year Treatment for Chronic Non-infectious Uveitis
YUTIQ® - 3 YEAR TREATMENT FOR CHRONIC NONINFECTIOUS UVEITIS Patients in the U.S. with Chronic Non-infectious Posterior Segment Uveitis ~60K–100K ~30,000 new cases of blindness per year in the U.S. 3rd leading cause of blindness in the U.S. Noninfectious uveitis is inflammation of the uveal tract and
Slide 20: YUTIQ Customer Demand Quarterly Trend
YUTIQ Customer Demand Quarterly Trend Units Shipped Q3’20 data through August 2020 Month 1 and 2 of Quarter Month 3 of Quarter Covid-19 Closures Q3 Demand Through August 31
Slide 21: U.S. Cataract Surgery Large and Growing
U.S. Cataract Surgery Large and Growing * Based upon company estimates for 2018. Source: imaged from the American Optometric Association. DEXYCU® CATARACT SURGERY MARKET Cataract Surgeries in 2018 3.8 Million* 8% annual growth rate in the U.S. Most performed surgery in the U.S. Baby boomers; longer
Slide 22: DEXYCU Customer Demand Quarterly Trend
DEXYCU Customer Demand Quarterly Trend Units Shipped Q3’20 data through end of August First 2 months of Quarter Third month of Quarter Covid-19 Closures ~3K units is largest 2-month customer demand since launch
Slide 23: DEXYCU - Expanding Product Reach
DEXYCU - EXPANDING PRODUCT REACH ImprimisRX - Commercial Alliance, August 2020 Focus on volume-based agreements with ambulatory surgical centers and integrated healthcare networks Latest strategic purchase and marketing agreement secured with Vantage Outsourcing in August 2020 One of Largest Integra
Slide 24: Company Overview
COMPANY OVERVIEW Ocular Disease Focus Portfolio of commercial- and clinical-stage assets targeting attractive areas of unmet need in ocular diseases Compelling Pipeline Includes EYP-1901 a potential six-month sustained release anti-VEGF treatment for wet age-related macular degeneration positioned f
EyePoint Pharmaceuticals — Cantor Virtual Healthcare Conference 2020 on 6ix